Johnson & Johnson stated that there are at least three tailwinds for the Innovative Medicines business through 2026.
Johnson & Johnson’s (NYSE:JNJ) shares came under pressure, despite the fourth-quarter revenue beat and in-line 2026 guidance, mainly due to stock outperformance ahead of the print and developments around the talc litigation, according to Goldman Sach… [1186 chars]
Source: Benzinga | Published: 2026-01-22T16:03:25Z
Credit: Benzinga
